MX2015007065A - Methods and compositions for treating hiv-associated diarrhea. - Google Patents

Methods and compositions for treating hiv-associated diarrhea.

Info

Publication number
MX2015007065A
MX2015007065A MX2015007065A MX2015007065A MX2015007065A MX 2015007065 A MX2015007065 A MX 2015007065A MX 2015007065 A MX2015007065 A MX 2015007065A MX 2015007065 A MX2015007065 A MX 2015007065A MX 2015007065 A MX2015007065 A MX 2015007065A
Authority
MX
Mexico
Prior art keywords
subject
methods
hiv
composition
associated diarrhea
Prior art date
Application number
MX2015007065A
Other languages
Spanish (es)
Inventor
Bortey Enoch
Forbes William
Golden Pam
Original Assignee
Napo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Napo Pharmaceuticals Inc filed Critical Napo Pharmaceuticals Inc
Publication of MX2015007065A publication Critical patent/MX2015007065A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Provided herein are methods for treating HIV- associated or highly active antiretroviral therapy (HAART)-associated diarrhea in an HIV positive subject by administering a composition comprising crofelemer to the subject wherein the composition has minimal drug-drug interactions with at least one other compound concurrently administered to the subject to treat an HIV infection. Also provided are methods for treating HIV- associated or highly active antiretroviral therapy (HAART)- associated diarrhea in an HIV positive subject by administering a composition comprising crofelemer to the subject, wherein the composition does not significantly inhibit the activity of at least one other compound concurrently administered to the subject to treat an HIV infection.
MX2015007065A 2012-12-07 2013-03-15 Methods and compositions for treating hiv-associated diarrhea. MX2015007065A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261734901P 2012-12-07 2012-12-07
PCT/US2013/032395 WO2014088629A1 (en) 2012-12-07 2013-03-15 Methods and compositions for treating hiv-associated diarrhea

Publications (1)

Publication Number Publication Date
MX2015007065A true MX2015007065A (en) 2017-03-01

Family

ID=50881628

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015007065A MX2015007065A (en) 2012-12-07 2013-03-15 Methods and compositions for treating hiv-associated diarrhea.

Country Status (6)

Country Link
US (1) US20140163096A1 (en)
EP (1) EP2928560A4 (en)
JP (1) JP2016505561A (en)
CA (1) CA2893070A1 (en)
MX (1) MX2015007065A (en)
WO (1) WO2014088629A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090009292A (en) 2006-05-01 2009-01-22 나포 팔마큐티칼스 인코퍼레이션 Method for treatment of constipation-predominant irritable bowel syndrome
PT2529626T (en) 2006-05-01 2018-02-27 Napo Pharmaceuticals Inc Compositions and methods for treating or preventing colon cancer
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
BR112013010774A2 (en) 2010-10-31 2017-03-21 Napo Pharmaceuticals Inc "uses of crofelemer in the treatment of HIV-associated diarrhea"
WO2015155673A1 (en) * 2014-04-08 2015-10-15 Teva Pharmaceutical Industries Ltd Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
US10380937B2 (en) 2015-08-26 2019-08-13 Apple Inc. Multi-zoned variable VCOM control
WO2020180424A1 (en) 2019-03-04 2020-09-10 Iocurrents, Inc. Data compression and communication using machine learning

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2474056A1 (en) * 2002-01-24 2003-07-31 Sangstat Medical Corporation Combination therapy for treatment of hiv infection
CA2633417A1 (en) * 2005-12-15 2007-06-21 Bayer Healthcare Ag Diaryl ureas for treating virus infections
US7928115B2 (en) * 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
BR112013010774A2 (en) * 2010-10-31 2017-03-21 Napo Pharmaceuticals Inc "uses of crofelemer in the treatment of HIV-associated diarrhea"

Also Published As

Publication number Publication date
EP2928560A1 (en) 2015-10-14
JP2016505561A (en) 2016-02-25
EP2928560A4 (en) 2016-06-01
US20140163096A1 (en) 2014-06-12
WO2014088629A1 (en) 2014-06-12
CA2893070A1 (en) 2014-06-12

Similar Documents

Publication Publication Date Title
MX2015007065A (en) Methods and compositions for treating hiv-associated diarrhea.
AR093386A1 (en) COMPOSITION TO TREAT DIABETES OR DIABESITY INCLUDING AN OXINTOMODULIN ANALOG AND TREATMENT METHOD
NZ702663A (en) Nuclear transport modulators and uses thereof
MX2016004492A (en) Inhibitors of human immunodeficiency virus replication.
MX365939B (en) Nuclear transport modulators and uses thereof.
PH12014501702A1 (en) Imidazopyrrolidinone compounds
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
BR112015011933A2 (en) synergistic bacterial compositions and methods of production and use thereof
BR112013027119A8 (en) new ligand-drug conjugates (adcs) and their use
PH12015501887B1 (en) Novel bacteriophage and antibacterial composition comprising the same
AR108021A1 (en) ADJUSTMENTS OF ANTIBODY-ACTIVE PRINCIPLE (ADCS) OF KSP INHIBITORS WITH ANTI-B7H3 ANTIBODIES
PH12015501888A1 (en) Novel bacteriophage and antibacterial composition comprising the same
MX2017004580A (en) Synergistic auristatin combinations.
NZ702087A (en) Pharmaceutical compositions and treatment of mastitis
MX348184B (en) Methods and compositions for treating hiv-associated diarrhea.
MX2014000567A (en) Treatment of radiation injury using amnion derived adherent cells.
TW201613592A (en) Glucose metabolism ameliorating agent
NZ601559A (en) Platelet-derived growth factor compositions and methods for the treatment of tendinopathies
MX2020011107A (en) Glycosidase regimen for treatment of infectious disease.
NZ769854A (en) Use of polar lipids to treat or prevent gestational diabetes mellitus
MX343589B (en) Leukotoxin e/d as a new anti-inflammatory agent and microbicide.
MX2016007915A (en) Methods for treating an animal.
EA201590796A1 (en) FIBRINOLYTIC COMPOSITIONS, INCLUDING BROMELEIN AND NATTOKINAZ, FOR THE PREVENTION AND TREATMENT OF PHLEBOTHROMBOTIC CONDITIONS
WO2012006585A3 (en) Use of interleukin-15 to treat cardiovascular diseases
UA109944U (en) PHARMACEUTICAL COMPOSITION TO REDUCE THE N-OXIDE OF TRIMETHYLAMINE LEVEL

Legal Events

Date Code Title Description
GB Transfer or assignment

Owner name: NAPO PHARMACEUTICALS, INC.